#United States #Boston #oncology #digital health #Resilience Care

Resilience Care Expands into the U.S. Market

Resilience Care, a digital oncology company recognized for its innovation, has officially announced its expansion into the United States. Co-founded with the Gustave Roussy Institute — one of the leading cancer centers globally — the company is now poised to introduce its clinically validated platform intended to bridge the familiar gap faced in oncology care.

Having established a reputation across Europe, Resilience Care operates in over 200 clinical centers and has aided more than 35,000 patients. Their approach aims to tackle what the industry describes as the "between-visit blind spot," where critical patient information often goes unreported until the next appointment.

To spearhead this expansion, Resilience Care has appointed Greg Orr, who brings notable experience from his previous role as Chief Operating Officer at Jasper Health. Orr's background in enhancing digital health navigation will be instrumental as the team aims to dominate the U.S. oncology support landscape.

Joining Orr is an elite advisory board composed of veterans in the digital health sector. Among them are Eddie Martucci, a biotech entrepreneur known for his leadership roles in digital therapeutics, Jill DeSimone, a former president at Merck specializing in oncology, and Anne Ireland, a prominent nurse executive with extensive oncology experience. Together, they will provide invaluable insights to shape Resilience Care's strategy for penetrating the U.S. market.

The platform designed by Resilience Care focuses on delivering a tailored digital experience to patients, which includes real-time symptom tracking and adaptive treatment pathways. It not only enhances patient engagement but also increases the efficiency of healthcare teams. By providing ongoing management and education for low-grade symptoms, staff are able to prioritize higher-risk cases. Such practices drive significant improvements in nursing capacity and patient adherence rates, crucial for long-term treatment success.

Greg Orr emphasizes the importance of continuous communication in oncology care, stating, "Our mission is to eliminate clinical blind spots and transform the often chaotic communications into a structured process of clinical triage. This fundamental shift enables care teams to address burgeoning issues before they escalate into critical emergencies."

The effectiveness of Resilience Care's platform is backed by the insights of Dr. Ethan Basch, a leading oncologist and expert in Patient Reported Outcomes (PROs), who acknowledges that digital solutions substantially enhance patient outcomes and satisfaction levels. Research indicates that utilizing their system reduces hospitalizations and treatment-related toxicities, which in turn extends treatment durations.

Orr elaborates on the platform’s capabilities, noting, "Capturing patient-reported symptoms in a structured manner allows us to identify complications early, ensuring timely responses from our care teams. Our goal in the U.S. is to embed these practices into standard care protocols and provide ongoing support for both patients and healthcare providers."

About Resilience Care:
As a digital oncology company, Resilience Care is focused on eradicating gaps in the cancer treatment experience. Utilized in over 200 treatment centers worldwide, their platform facilitates remote symptom monitoring which allows care teams to detect treatment toxicities at early stages and react proactively. This, in turn, maximizes nursing efficiency, streamlines clinical workflows, and empowers patients with the support necessary to navigate their treatment journeys safely. The importance of data-driven care and real-time insights are at the core of Resilience Care's mission to drive improvements in both clinical outcomes and operational revenue in U.S. healthcare settings.